Paclitaxel-containing high-dose chemotherapy in high-risk breast cancer patients

Acta Oncologica

Volumn 39, Issue 1, 2000, Pages 47-52

  Greinix, Hildegard T ^a,d   Linkesch, Werner ^c   Seifert, Manfred ^a   Kubista, Ernst ^a   Czerwenka, Klaus ^a   Elahi, Fariborz ^a   Zielinski, Christoph ^b   Hoecker, Paul ^a   Steger, Günther ^b   Schulenburg, Axel ^a   Neumeister, Geralt ^c   Rabitsch, Werner ^a   Jakesz, Raimund ^a   Kalhs, Peter ^a  

^a Bone Marrow Transplantation Unit   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF GRAZ   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; INFECTION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS;

EID: 0034000717     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418600430969     Document Type: Article

References (31)

1. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-negative breast cancer. N Engl J Med 1995; 332: 901-6.
2. Fisher E, Sass R, Fisher B. Pathologic findings from the national surgical adjuvant project for breast cancers. Cancer 1984; 53: 712-23.
3. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-43.
4. Antman K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-10.
5. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-9.
6. Ayash LJ, Wheeler C, Fairclough D, et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043-9.
7. Elias AD, Ayash L, Anderson KC, et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79: 3036-44.
8. Shpall EJ, Jones RB, Bearman SI, et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
9. De Vries EG, Ten Vergert EM, Mastenbroek CG, Dalesio O, Rodenhuis S. Breast cancer studies in The Netherlands. Lancet 1996; 348: 407-8.
10. Hurd DD, Peters WP. Randomized, comparative study of high-dose (with autologous bone marrow support) versus low-dose cyclophosphamide, cisplatin, and carmustine as consolidation to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for patients with operable stage II or III breast cancer involving 10 or more axillary lymph nodes (CLGB Protocol 9082). Cancer and Leukemia Group B. J Natl Cancer Inst Monogr 1995; 19: 41-4.
11. Rodenhuis S, Richel DJ, Van der Wall E, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 1998; 352: 515-21.
12. Horwitz SB. Mechanism of action of Taxol. Trends Pharmacol Sci 1992; 13: 134-6.
13. Reichman BS, Seidman AD, Crown JPA, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11: 1943-51.
14. Milas L, Hunter NR, Kurdoglu B. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with Taxol. Cancer Chemother Pharmacol 1995; 35: 297-303.
15. McCloskey DE, Davidson NE. Paclitaxel-induced programmed cell death in human breast cancer cells. Proc Am Assoc Cancer Res 1995; 36: 416.
16. Holmes FA, Walters RS, Theriault RL. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797-805.
17. Berenson RJ, Andrews RG, Bensinger WI, et al. Selection of CD34+ marrow cells for autologous marrow transplantation. In: Dicke KA, (ed). Autologous bone marrow transplantation: Proc Fourth Int Symp. Houston, TX, University of Texas M.D. Anderson Hospital and Tumor Institute at Houston, 1989: 55-62.
18. Brugger W, Henschler R, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L. Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Blood 1994; 84: 1421-6.
19. Harbeck N, Untch M, Pache L, Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer 1994; 69: 566-71.
20. Miller AB, Hoogstraten B, Staquet W. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
21. Seidman AD, Norton L, Reichman BS, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995; 13: 1152-9.
22. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993; 20 (Suppl 3): 1-15.
23. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263-8.
24. Arbuck SG, Canetta R, Onetto N, Christian MC. Current dosage and schedule issues in the development of paclitaxel (Taxol). Semin Oncol 1993; 20 (Suppl 3): 31-9.
25. Holland HK, Dix SP, Geller RB, et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow stem-cell transplantation and comprehensive supportive care. J Clin Oncol 1996; 14: 1156-64.
26. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-95.
27. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-9.
28. Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-40.
29. Ross AA, Cooper BW, Lazarus HM, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605-10.
30. Brenner MK, Rill DR, Moen RC, et al. Gene marking to trace origin of relapse after autologous hone marrow transplantation. Lancet 1993; 341: 85-6.
31. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525-8.